Inovio Pharmaceuticals (INO) Profit After Tax (2010 - 2026)

Inovio Pharmaceuticals has reported Profit After Tax for 17 years, with the latest figure at -$19.7 million in Q1 2026.

• Quarterly Profit After Tax changed 0.03% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.0 million (up 11.94% YoY) and the FY2025 annual result came in at -$84.9 million, up 20.8% from the prior year.
• Profit After Tax eased to -$19.7 million in Q1 2026 per INO's latest filing, from $3.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at $3.8 million in Q4 2025 and troughed at -$108.5 million in Q2 2022.
• A 5-year average of -$36.9 million and a median of -$32.2 million in 2024 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 119.37% in 2025, down 80.79% in 2025.
• Over 5 years, Profit After Tax stood at -$54.5 million in 2022, then jumped by 54.09% to -$25.0 million in 2023, then grew by 22.48% to -$19.4 million in 2024, then jumped by 119.37% to $3.8 million in 2025, then sank by 624.76% to -$19.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$19.7 million, $3.8 million, and -$45.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.